Alginate oligosaccharide protects against enterotoxigenic Escherichia coli-induced porcine intestinal barrier injury

Alginate oligosaccharide (AOS) possesses various pharmaceutical benefits, making it an attractive candidate for biomedical applications. In the present study, we prepared AOS by depolymerising alginate; its degree of polymerisation mainly ranged from 2 to 8. We confirmed the enteroprotective potential of AOS against enterotoxigenic Escherichia coli (ETEC)-induced intestinal barrier injury in weaned pigs. Next, we illustrated the mechanisms underlying this effect of AOS using the porcine small intestinal epithelial cell line IPEC-J2. AOS potently reduced the binding of the bacteria-deprived endotoxin lipopolysaccharide (LPS) to the IPEC-J2 cell surface. Moreover, it suppressed the LPS-induced production of pro-inflammatory cytokines and the nuclear translocation of nuclear factor-kappa B (NF-kappa B) p65 in IPEC-J2 cells. These results indicate that AOS protects the intestinal epithelium from ETEC-induced inflammatory injury by preventing the activation of NF-kappa B, implying that AOS could be used as an anti-inflammatory agent for treating inflammation-related intestinal diseases in mammals.

Automated summary

The study demonstrates that alginate oligosaccharide can protect the intestinal mucosa from inflammatory injury induced by Escherichia coli and achieve this effect by inhibiting the activation of NF-kappa B.